Neurological Biomarkers Market: By Type (Metabolomic Biomarkers, Proteomic Biomarkers, Genomic Biomarkers, Imaging Biomarkers, Others), By Application (Alzheimer's, Autism Spectrum Disorder and Parkinson's, Multiple Sclerosis), By End-use (Clinical Diagnostic Centers, Hospital Laboratories, Research Organizations, Others)  and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Neurological Biomarkers Market size was valued at USD 7 billion in 2022 and is poised to grow at a CAGR of 12.9% from 2023-2029. The global neurological biomarkers market is anticipated to record fast growth with the current neurological disorder conditions all across the world. A huge percentage of people are affected by neurological disorders and consequently causing major disabilities around the world. Because of the increasing cases of neurological disorders, demand for biomarkers is increased for measuring biological states. These biomarkers are also utilized for indication of biological and pathogenic process in terms of healing intervention. They are also used in combination to know the illness state of the person. Biomarkers are also used for those who are suffering from acute ischemic stroke, subarachnoid hemorrhage, and brain injury and intracerebral hemorrhage. The recovery of the patients is totally depending on their mitigation. In such type of situation, a delay can be there in proper examination of the patients due to the complexities. This situation calls for the use of biomarkers and promotes the biomarkers market. The research examines COVID-19 in light of changes in consumer behaviour and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. The revised report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.

Global Neurological Biomarkers Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

12.9%

Largest Market

North America

Fastest Growing Market

Europe
Neurological Biomarkers Market Dynamics

The global neurological biomarkers market is expected to witness a rapid growth with the prevailing neurological disorder cases all over the world. A major percentage of world population is affected by neurological disorders; this in turn is causing major disabilities globally. Due to the high incidence of neurological disorders, there is the need for biomarkers as biomarkers measure biological states and are used for indication of both pathogenic as well as normal biological process in terms of therapeutic intervention. Biomarkers can also be utilized in combination for accessing the state of the disease of an individual. Urge in research proposals enables neurological biomarkers market to remain active. Increasing demand for personalized medicine to treat neurological disorders also boom the market growth. Another market driving factor is growing demand for non-invasive diagnostic methods for Parkinson's and Alzheimer's. Increasing demand for genomics biomarker will also impel the market growth. On the other hand, strict government rules will hinder the market growth. Emerging legal problems with early identification of Alzheimer's and Parkinson's illnesses can also be a restricting factor for the market growth.

Global Neurological Biomarkers Market Segmentation

By Type
  • Metabolomic Biomarkers
  • Proteomic Biomarkers
  • Genomic Biomarkers
  • Imaging Biomarkers
  • Others
By Application
  • Parkinson's Disease
  • Multiple Sclerosis
  • Alzheimer's Disease
  • Autism Spectrum Disorders
  • Others
By End User
  • Clinical Diagnostic Centers
  • Hospital Laboratories
  • Research Organizations
  • Others
By Geography
  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

The neurological biomarkers market size was valued at USD 7 billion in 2022

The neurological biomarkers market key players are Abbott Laboratories, Myriad Rbm, Inc, Athena Diagnostics, Immunarray Pvt. Ltd, Acumen Pharmaceuticals Inc, Banyan Biomarkers Inc

Increasing Product Launches and Approvals

Key Features of the Reports

  • The neurological biomarkers market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Neurological Biomarkers Market Introduction 
2.1.Global Neurological Biomarkers Market  - Taxonomy
2.2.Global Neurological Biomarkers Market  - Definitions
2.2.1.Type
2.2.2.Application
2.2.3.End User
2.2.4.Region
3.Global Neurological Biomarkers Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Neurological Biomarkers Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Neurological Biomarkers Market  By Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Metabolomic Biomarkers
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Proteomic Biomarkers
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Genomic Biomarkers
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Imaging Biomarkers
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Others
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6.Global Neurological Biomarkers Market  By Application, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Parkinson's Disease
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Multiple Sclerosis
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Alzheimer's Disease
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Autism Spectrum Disorders
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Neurological Biomarkers Market  By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Clinical Diagnostic Centers
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Hospital Laboratories
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Research Organizations
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Neurological Biomarkers Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Neurological Biomarkers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Metabolomic Biomarkers
9.1.2.Proteomic Biomarkers
9.1.3.Genomic Biomarkers
9.1.4.Imaging Biomarkers
9.1.5.Others
9.2.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Parkinson's Disease
9.2.2.Multiple Sclerosis
9.2.3.Alzheimer's Disease
9.2.4.Autism Spectrum Disorders
9.2.5.Others
9.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Clinical Diagnostic Centers
9.3.2.Hospital Laboratories
9.3.3.Research Organizations
9.3.4.Others
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Neurological Biomarkers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Metabolomic Biomarkers
10.1.2.Proteomic Biomarkers
10.1.3.Genomic Biomarkers
10.1.4.Imaging Biomarkers
10.1.5.Others
10.2.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Parkinson's Disease
10.2.2.Multiple Sclerosis
10.2.3.Alzheimer's Disease
10.2.4.Autism Spectrum Disorders
10.2.5.Others
10.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Clinical Diagnostic Centers
10.3.2.Hospital Laboratories
10.3.3.Research Organizations
10.3.4.Others
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Neurological Biomarkers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Metabolomic Biomarkers
11.1.2.Proteomic Biomarkers
11.1.3.Genomic Biomarkers
11.1.4.Imaging Biomarkers
11.1.5.Others
11.2.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Parkinson's Disease
11.2.2.Multiple Sclerosis
11.2.3.Alzheimer's Disease
11.2.4.Autism Spectrum Disorders
11.2.5.Others
11.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Clinical Diagnostic Centers
11.3.2.Hospital Laboratories
11.3.3.Research Organizations
11.3.4.Others
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Neurological Biomarkers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Metabolomic Biomarkers
12.1.2.Proteomic Biomarkers
12.1.3.Genomic Biomarkers
12.1.4.Imaging Biomarkers
12.1.5.Others
12.2.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Parkinson's Disease
12.2.2.Multiple Sclerosis
12.2.3.Alzheimer's Disease
12.2.4.Autism Spectrum Disorders
12.2.5.Others
12.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Clinical Diagnostic Centers
12.3.2.Hospital Laboratories
12.3.3.Research Organizations
12.3.4.Others
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Neurological Biomarkers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Metabolomic Biomarkers
13.1.2.Proteomic Biomarkers
13.1.3.Genomic Biomarkers
13.1.4.Imaging Biomarkers
13.1.5.Others
13.2.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Parkinson's Disease
13.2.2.Multiple Sclerosis
13.2.3.Alzheimer's Disease
13.2.4.Autism Spectrum Disorders
13.2.5.Others
13.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Clinical Diagnostic Centers
13.3.2.Hospital Laboratories
13.3.3.Research Organizations
13.3.4.Others
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Abbott Laboratories
14.2.2.Myriad Rbm, Inc
14.2.3.Athena Diagnostics
14.2.4.Immunarray Pvt. Ltd
14.2.5.Acumen Pharmaceuticals Inc
14.2.6.Banyan Biomarkers Inc
15. Research Methodology 
16. Appendix and Abbreviations 
  • Abbott Laboratories
  • Myriad Rbm, Inc
  • Athena Diagnostics
  • Immunarray Pvt. Ltd
  • Acumen Pharmaceuticals Inc
  • Banyan Biomarkers Inc

Adjacent Markets